<DOC>
	<DOCNO>NCT00573404</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate sunitinib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose imatinib mesylate give together sunitinib treat patient gastrointestinal stromal tumor .</brief_summary>
	<brief_title>Imatinib Mesylate Sunitinib Treating Patients With Gastrointestinal Stromal Tumors</brief_title>
	<detailed_description>OBJECTIVES : - To determine maximum tolerate dose imatinib mesylate combination sunitinib malate patient gastrointestinal stromal tumor . - To determine toxicity regimen patient . - To determine antitumor activity patient treat regimen . OUTLINE : This dose-escalation study imatinib mesylate . Patients receive oral sunitinib malate daily day 1-14 course 1 day 1-42 subsequent course . Beginning course 2 , patient also receive oral imatinib mesylate twice daily day 1-42 . Courses repeat every 6 week absence unacceptable toxicity . Blood sample collect day 15 day 43 pharmacokinetics . After completion study treatment , patient follow every 6 month .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy prove gastrointestinal stromal tumor Patients previously treat imatinib mesylate must document progression disease Untreated disease allow Must ≥ 1 measurable lesion RECIST No history know brain metastasis , spinal cord compression , carcinomatous meningitis , evidence symptomatic brain leptomeningeal disease screen CT MRI scan PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,500/μL Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 150,000/μL Total serum bilirubin ≤ 2.0 mg/dL Serum calcium ≤ 12.0 mg/dL Serum creatinine ≤ 1.8 mg/dL AST ALT ≤ 3 time upper limit normal ( ULN ) ( 5 time ULN liver function abnormality due underlying malignancy ) Able take oral medication Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No grade 3 hemorrhage within past 4 week No myocardial infarction , severe unstable angina , coronary peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism within past 6 month No ongoing cardiac dysrhythmias ≥ grade 2 No prolong QTc interval baseline EKG No hypertension control medication ( BP &gt; 150/100 mm Hg , despite medical therapy ) No preexist thyroid abnormality thyroid function maintain normal range medication No known HIV AIDSrelated illness active infection No severe , acute , chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator , preclude study entry No malabsorption syndrome No prior intolerance imatinib mesylate toxicity necessitate dose modification No prior intolerance sunitinib malate toxicity necessitate dose modification PRIOR CONCURRENT THERAPY : Recovered acute toxic effect prior chemotherapy , radiotherapy , surgical procedure No major surgery radiotherapy within past 4 week No concurrent treatment another clinical trial , except supportive care trial nontreatment trial ( e.g. , quality life ) No concurrent ketoconazole agent know induce CYP3A4 No concurrent theophylline phenobarbital and/or agent metabolize cytochrome P450 system No ongoing therapeutic dos coumadin , except lowdose oral coumadin 2 mg daily thrombosis prophylaxis No concurrent Hypericum perforatum ( St. John 's wort ) herbal medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>gastrointestinal stromal tumor</keyword>
</DOC>